Business Description
Arch Therapeutics Inc
NAICS : 325413
SIC : 2836
ISIN : US03939W2089
Description
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -8.99 | |||||
| Debt-to-Equity | -0.75 | |||||
| Debt-to-EBITDA | -1.08 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -103.82 | |||||
| Beneish M-Score | -29.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 36.6 | |||||
| 3-Year EPS without NRI Growth Rate | 17.5 | |||||
| 3-Year FCF Growth Rate | 41.1 | |||||
| 3-Year Book Growth Rate | -1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1192.72 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | |||||
| Quick Ratio | 0.01 | |||||
| Days Inventory | 5402 | |||||
| Days Payable | 10776.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -69.4 | |||||
| Shareholder Yield % | -316.59 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.93 | |||||
| Operating Margin % | -3169.13 | |||||
| Net Margin % | -8230.2 | |||||
| FCF Margin % | -2484.56 | |||||
| ROA % | -740.34 | |||||
| ROIC % | -69.91 | |||||
| ROC (Joel Greenblatt) % | -271375 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.08 | |||||
| PS Ratio | 9.09 | |||||
| EV-to-EBIT | -1.23 | |||||
| EV-to-EBITDA | -1.23 | |||||
| EV-to-Revenue | 71.76 | |||||
| EV-to-FCF | -2.77 | |||||
| Earnings Yield (Greenblatt) % | -81.41 | |||||
| FCF Yield % | -190.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arch Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.149 | ||
| EPS (TTM) ($) | -2.864 | ||
| Beta | -0.46 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0.8 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.8 - 0.8 | ||
| Shares Outstanding (Mil) | 4.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arch Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arch Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arch Therapeutics Inc Frequently Asked Questions
What is Arch Therapeutics Inc(LTS:0HHJ)'s stock price today?
The current price of LTS:0HHJ is $0.80. The 52 week high of LTS:0HHJ is $0.80 and 52 week low is $0.80.
When is next earnings date of Arch Therapeutics Inc(LTS:0HHJ)?
The next earnings date of Arch Therapeutics Inc(LTS:0HHJ) is 2025-02-20 Est..
Does Arch Therapeutics Inc(LTS:0HHJ) pay dividends? If so, how much?
Arch Therapeutics Inc(LTS:0HHJ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers